Form 4: Director Konowiecki Granted Alignment Healthcare RSUs

Alignment Healthcare director Joseph S. Konowiecki was granted 24,868 restricted stock units, vesting on March 13, 2027, with deferral of share receipt.

Summary

• Joseph S. Konowiecki, a Director of Alignment Healthcare, Inc. (ALHC), was granted 24,868 restricted stock units (RSUs).
• Each RSU represents the right to receive one share of the company's Common Stock.
• The RSUs are scheduled to vest entirely on March 13, 2027, which is the first anniversary of the grant date (March 13, 2026).
• Vesting is contingent on Mr. Konowiecki remaining a member of the Board of Directors until the vesting date.
• Mr. Konowiecki has elected to defer the actual receipt of the underlying shares for three years from the vesting date, or earlier upon separation of service or a change of control of the Company.
• Following this transaction, Mr. Konowiecki beneficially owns 1,081,009 shares of Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as it signifies continued alignment of a director's interests with long-term shareholder value through equity compensation and a deferral election.

Positives

• The grant of 24,868 restricted stock units to a director aligns management's interests with long-term shareholder value.
• The deferral of share receipt by the director indicates a long-term commitment to the company's performance.

Risks

• The vesting of the restricted stock units is contingent on the reporting person continuing to serve as a member of the Board of Directors prior to the vesting date.

Future Outlook

The director's election to defer receipt of the underlying shares for three years suggests a long-term perspective on the company's future performance and value.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units, are a common form of executive and director compensation in the healthcare technology sector, aiming to incentivize long-term performance and align leadership interests with shareholder returns. This practice is consistent across publicly traded companies like Teladoc Health (TDOC) or Amwell (AMWL) which also utilize equity compensation to retain and motivate key personnel.

Comparison to Industry Standards

• Equity compensation for directors, particularly through restricted stock units, is a standard practice across U.S. public companies, including those in the healthcare sector.
• The vesting schedule (one year) is common for annual director grants, similar to practices at companies like Humana (HUM) or Centene (CNC) for their non-employee directors.
• The deferral election is also a common feature in director compensation plans, allowing for tax planning and demonstrating a long-term commitment, comparable to deferral options seen at major corporations across various industries.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders if the stock value increases.

Next Steps

• The 24,868 restricted stock units are scheduled to vest on March 13, 2027.
• The underlying shares will be received by the director three years after vesting, or earlier upon separation of service or a change of control.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice. While it indicates continued alignment of interests, it does not present new information that would fundamentally alter the investment thesis for Alignment Healthcare, Inc. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Alignment Healthcare, ALHC, Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Joseph S. Konowiecki